Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche bets $4.3 billion on Spark in gene therapy move

share with twitter share with LinkedIn share with facebook
share via e-mail
02/25/2019 | 04:02am EDT
FILE PHOTO - Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

ZURICH (Reuters) - Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion (£3.3 billion) deal that will give the Swiss drugmaker a foothold in gene therapy.

Roche will pay $114.50 per share for Spark, more than twice the U.S. company closing price on Feb. 22, the Swiss company said on Monday.

Basel-based Roche is buying Spark and its portfolio of treatments for blindness, haemophilia and neurodegenerative diseases, among other conditions, as rivals including Novartis, also move aggressively into gene therapy.

"Spark Therapeutics' proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases," Roche Chief Executive Severin Schwan said.

Schwan is counting on new medicines, including gene therapies, to help compensate for patent losses on his $21-billion-per-year trio of cancer medicines Rituxan, Herceptin and Avastin, that are facing competition from cheaper copies.

Roche, the biggest cancer drugs maker, was late to the game in immuno-oncology where Merck's Keytruda is becoming the dominant player and has eclipsed Roche's own product, Tecentriq, that seeks to harness the body's immune system to fight cancer.

Bank Vontobel analysts said the Spark deal would give Roche a proven platform for getting gene therapies to market, but did not come without risks -- including getting beaten to market by rivals with similar treatments in the works.

Roche shares were 0.8 percent lower by 0840 GMT.

Gene therapies use specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.

Spark has an approved gene therapy treatment Luxturna, which is sold in the United States by Spark and elsewhere by Novartis after its approval in 2017.

Luxturna targets a rare genetic disease, Leber's congenital amaurosis, that causes blindness in about 1 in 200,000 people.

Loss-making Spark had $51.6 million in revenue in the first nine months of 2018 from Luxturna and also had income from a deal with Pfizer, which it is partnering on another gene therapy for haemophilia B.

Philadelphia-based Spark's shares are up about 30 percent this year. The U.S.-company's stock tumbled last year after two of 12 patients showed an unfavourable immune response when treated with a higher dose of Spark's haemophilia therapy SPK-8011.


Roche's Spark deal, seen closing in the second quarter, follows Novartis's $8.7 billion purchase of U.S.-based Avexis last year, also to gain a platform of gene therapies for disorders including spinal muscular atrophy.

Novartis has made gene therapy one of its focus areas, giving it a head start on Roche. U.S. approval of Novartis's SMA medicine is slated for coming months.

Among Spark's top drug hopefuls is SPK-8011, for haemophilia A, expected to start Phase 3 trials in 2019. It is also working on treatments for Pompe disease, blindness-causing choroideremia and Huntington's disease.

"The needs of patients and families living with genetic diseases are immediate and their needs vast," Spark Chief Executive Jeffrey Marrazzo said.

"With its worldwide reach and extensive resources, Roche will help us accelerate the development of more gene therapies."

Roche already sells Hemlibra against haemophilia A that helps stop bleeding in patients with the life-threatening genetic disorder that prevents their blood from clotting. Hemlibra, approved in 2017, had 224 million Swiss francs ($224.18 million) in sales last year.

With Spark, Roche enters a crowded haemophilia gene therapy market that could become a big competitor to Hemlibra, as other players - Biomarin Pharma, Uniqure NV and Sangamo Therapeutics - also have gene therapies in the works.

"We view Biomarin likely first to market," Vontobel analyst Stefan Schneider said. "We view the market opportunity big enough to accommodate more than one gene therapy - but a favourable safety profile will likely win gold."

(Reporting by John Miller; editing by Thomas Seythal/Rashmi Aich/Jane Merriman)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.05% 81.02 Delayed Quote.5.98%
NOVARTIS 0.62% 84.7 Delayed Quote.13.31%
ROCHE HOLDING LTD. 0.80% 269.5 Delayed Quote.9.84%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
10:50aMERCK AND : puts $1B more into oncology, with kidney cancer a focus
06:38aMERCK AND : Mercks Keytruda fails in Phase III triple-negative breast cancer stu..
04:37aMERCK AND : UKs LifeArc charity nets $1.3 billion Keytruda windfall
05/22MERCK AND : Peloton Therapeutics - Merck to Acquire Peloton Therapeutics, Bolste..
05/22MERCK FOUNDATION : Announces Grant to American Cancer Society to Improve Access ..
05/21MARKET SNAPSHOT: Dow Logs 200-point Gain As Demand For Tech, Energy Stocks Ov..
05/21MERCK AND : buys Peloton to expand its kidney cancer treatment portfolio
05/21GLOBAL MARKETS LIVE : Huawei, Sprint, T-Mobile, Tesla…
05/21MERCK AND : to Buy Cancer Drug Maker Peloton Therapeutics -- 2nd Update
05/21MERCK AND : Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA Monotherapy..
More news
Financials ($)
Sales 2019 44 685 M
EBIT 2019 15 007 M
Net income 2019 10 549 M
Debt 2019 18 245 M
Yield 2019 2,72%
P/E ratio 2019 19,52
P/E ratio 2020 16,89
EV / Sales 2019 5,07x
EV / Sales 2020 4,75x
Capitalization 208 B
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 89,2 $
Spread / Average Target 10%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.03%368 416
PFIZER-4.54%233 461
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
ABBVIE-11.50%120 617